Faisal Rashid

Faisal Rashid asked if Kymera plans to provide updates on enrollment progress for the KT-621 Phase IIb AD and asthma studies as sites become operational.

Answer

CEO Nello Mainolfi stated that Kymera does not plan to provide ongoing updates on enrollment for the KT-621 Phase IIb studies unless there is a material deviation from expectations.

Faisal Rashid asked if Kymera expects to provide any updates or color on the enrollment progress for the KT-621 Phase 2b studies.

Answer

Nello Mainolfi, Founder, President, and CEO, stated that Kymera does not plan to provide ongoing updates on enrollment unless there is a material deviation from their expectations.